Krystexxa® (pegloticase)

Krystexxa (pegloticase) is covered for adults with chronic gout refractory to conventional therapy and is not covered if used with other uric‑acid–lowering drugs. Key requirements: initial approval (6 months) needs ≥1 tophus or ≥2 flares in the past year, documented inadequate response (SUA >6 mg/dL) after 3‑month trials of a xanthine oxidase inhibitor and a uricosuric agent (unless contraindicated/intolerant or renal insufficiency), concomitant use of methotrexate, leflunomide, azathioprine, or mycophenolate, rheumatology/nephrology prescribing or consultation; reauthorization (12 months) requires SUA <6 mg/dL and continued immunomodulator use.

"Krystexxa is indicated for the treatment of chronic gout in adult patients refractory to conventional therapy."

Sign up to see full coverage criteria, indications, and limitations.